Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 49, Issue 2 (Feb 2011)

Issues

High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry

Maria Chiara Mimmi
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
  • M.C. Mimmi and P. Picotti contributed equally.
/ Paola Picotti
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
  • M.C. Mimmi and P. Picotti contributed equally.
  • P.P. Present address: Institute of Molecular Systems Biology, ETH Zurich, Zurich 8093, Switzerland.
/ Alessandra Corazza
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
/ Elena Betto
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
/ Carlo E. Pucillo
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
/ Laura Cesaratto
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
/ Carla Cedolini
  • Azienda Ospedaliera Universitaria di Udine (AOUD), Udine, Italy
/ Viviana Londero
  • Azienda Ospedaliera Universitaria di Udine (AOUD), Udine, Italy
/ Chiara Zuiani
  • Azienda Ospedaliera Universitaria di Udine (AOUD), Udine, Italy
  • Dipartimento di Ricerche Mediche e Morfologiche, Università di Udine, Udine, Italy
/ Massimo Bazzocchi
  • Azienda Ospedaliera Universitaria di Udine (AOUD), Udine, Italy
  • Dipartimento di Ricerche Mediche e Morfologiche, Università di Udine, Udine, Italy
/ Gennaro Esposito
  • Dipartimento di Scienze e Tecnologie Biomediche, Università di Udine, Udine, Italy
  • MATI Centre of Excellence, Università di Udine, Udine, Italy
  • Email:
Published Online: 2010-12-14 | DOI: https://doi.org/10.1515/CCLM.2011.060

Abstract

Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures.

Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution 1H NMR spectroscopy to complement the mass spectrometry results.

Results: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease.

Conclusions: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter.

Keywords: breast cancer; breast tissue metabonomics; choline metabolites; mass spectrometry metabonomics; tumor marker detection by nuclear magnetic resonance and mass spectrometry

About the article

Corresponding author: Gennaro Esposito, Dipartimento Scienze e Tecnologie Biomediche, Università di Udine, P.le Kolbe, 4, 33100 Udine, Italy Phone: +39 0432494321, Fax: +39 0432494301


Received: 2010-02-12

Accepted: 2010-08-17

Published Online: 2010-12-14

Published in Print: 2011-02-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.060. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Gloria Pelizzo, Maria Chiara Mimmi, Maurizio Ballico, Mario Marotta, Ilaria Goruppi, Jose Louis Peiro, Elisa Zambaiti, Federico Costanzo, Erika Andreatta, Elena Tonin, and Valeria Calcaterra
The Journal of Maternal-Fetal & Neonatal Medicine, 2014, Page 1
[2]
Maria Chiara Mimmi, Maurizio Ballico, Ghassan Nakib, Valeria Calcaterra, Jose Louis Peiro, Mario Marotta, and Gloria Pelizzo
ISRN Analytical Chemistry, 2014, Volume 2014, Page 1
[3]
Duo-jiao Wu, Bi-jun Zhu, and Xiang-dong Wang
Journal of Clinical Bioinformatics, 2011, Volume 1, Number 1, Page 30

Comments (0)

Please log in or register to comment.
Log in